Ganesh Benzoplast Q1FY27: consolidated PAT down 3% YoY on margin squeeze, revenue +23%

Ganesh Benzoplast's consolidated Q1FY27 revenue rose 22.9% YoY to ₹117.50 Cr (₹95.62 Cr) and 5.4% QoQ (₹111.47 Cr), but consolidated PAT slipped 3.0% YoY to ₹17.58 Cr (₹18.13 Cr) — a ~6.5% decline once adjusted for a ₹0.95 Cr one-off loss embedded in the year-ago quarter's base — even as PAT rose 14.9% QoQ from ₹15.29 Cr. Basic EPS was ₹2.44 versus ₹2.52 a year ago. Standalone tells the same story: revenue up 23.5% YoY to ₹70.34 Cr, PAT down 4.6% YoY to ₹13.44 Cr, so standalone and consolidated are not materially diverging this quarter. There is no formal published Street consensus for this quarter that we could locate — MarketsMOJO carries a 'Hold' rating but no specific PAT/EPS estimate, so vsStreet is unknown rather than assumed. The margin story is exactly what management flagged on the Q4FY26 call: EBITDA-level margin (OPM) compressed to 22.98% from 29.44% a year ago, and net margin to 14.32% from 17.96%, driven almost entirely by the LST (port logistics/EPC/wharfage) division — its segment revenue grew 18.5% YoY to ₹54.80 Cr but segment PBIT fell 15.0% YoY to ₹17.90 Cr, pulling the division's margin down to 32.7% from 45.5% a year ago. That's consistent with the 30-year JNPT rental reset management cited as the margin drag when it guided a 2-3 year recovery path in the prior concall. The Chemical division, by contrast, grew revenue 27.0% YoY to ₹62.69 Cr with segment PBIT up 13.3% YoY to ₹8.15 Cr — comparatively resilient. Sequentially, both OPM (18.44%→22.98%) and NPM (13.14%→14.32%) improved from Q4FY26, an early signal — not yet confirmation — of the margin recovery management projected. No management press release commentary was available with this filing to cross-check against the numbers. The quarter's other disclosures are largely non-financial: the company confirmed no deviation in utilization of preferential-issue funds, NCLAT dismissed Progfin's insolvency appeal against the company (removing an overhang), and the trading window closed ahead of results as usual. The auditors' limited-review reports (standalone and consolidated) both carry an unmodified Emphasis of Matter on the FY24 FIR/EOW complaint concerning loans allegedly routed through an unauthorized GBL Chemical bank account — the company's petition to quash the FIR remains pending before the Delhi High Court, with no change in status this quarter. On balance this quarter tracks management's own guidance rather than beating or missing it: revenue growth continued as projected, and margin compression was concentrated exactly where guided (LST/JNPT), with the first sequential signs of the guided multi-year recovery. The next few quarters need to show OPM continuing back toward the ~29% level of a year ago for that recovery thesis to hold.